Segmentation by type classifies the service offerings into five methodological groups, each influencing market composition through technology adoption rates. Structure‑based virtual screening (SBVS) remains the cornerstone, employing protein‑target coordinates to rank ligand fits; it commands the highest utilization due to its mechanistic relevance. Ligand‑based virtual screening (LBVS) follows, exploiting known active chemotypes to infer similarity and activity, especially when structural data are scarce. Hybrid approaches combine SBVS and LBVS to improve hit rates, attracting mid‑size biotech firms seeking balanced risk. AI‑driven screening—including deep‑learning models for affinity prediction—represents a fast‑growing niche, driven by advances in computational power and data availability. Cloud‑based platforms provide scalable infrastructure, enabling on‑demand processing and collaborative workflows. Collectively, these types determine service pricing structures, investment priorities, and the competitive landscape within the Virtual Screening Technology Service market.